Equities

4Dmedical Ltd

4Dmedical Ltd

Actions
  • Price (USD)0.34
  • Today's Change0.00 / 0.00%
  • Shares traded1.40k
  • 1 Year change-27.38%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 13:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

4DMedical Limited is an Australia-based medical technology company. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. It initiated the commercial rollout of XV LVAS with I-MED Radiology Network (I-MED), which is a diagnostic imaging provider with approximately 250 clinics nationwide. The Company provides its lung imaging technology to other selected clinics across the I-MED network.

  • Revenue in AUD (TTM)3.75m
  • Net income in AUD-35.98m
  • Incorporated2012
  • Employees--
  • Location
    4Dmedical LtdLevel 7 Melbourne Connect700 Swanston StreetMELBOURNE 3053AustraliaAUS
  • Phone+61 39545-5940
  • Websitehttps://4dmedical.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4DX:ASX since
announced
Transaction
value
Imbio LLCDeal completed11 Dec 202311 Dec 2023Deal completed-51.05%69.30m
Data delayed at least 20 minutes, as of Nov 22 2024 04:05 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.